Ramakanth Sarabu
Hoffmann-La Roche Inc.
pRED, Pharma Research & Early Development
DTA Metabolism
United States
Name/email consistency: high
- Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients. Sarabu, R., Bizzarro, F.T., Corbett, W.L., Dvorozniak, M.T., Geng, W., Grippo, J.F., Haynes, N.E., Hutchings, S., Garofalo, L., Guertin, K.R., Hilliard, D.W., Kabat, M., Kester, R.F., Ka, W., Liang, Z., Mahaney, P.E., Marcus, L., Matschinsky, F.M., Moore, D., Racha, J., Radinov, R., Ren, Y., Qi, L., Pignatello, M., Spence, C.L., Steele, T., Tengi, J., Grimsby, J. J. Med. Chem. (2012)
- Novel glucokinase activators: a patent review (2008 - 2010). Sarabu, R., Berthel, S.J., Kester, R.F., Tilley, J.W. Expert. Opin. Ther. Pat (2011)
- Anglo-Swedish Medicinal Chemistry - second symposium. Sarabu, R. IDrugs (2005)
- Targeting glucokinase activation for the treatment of type 2 diabetes--a status review. Sarabu, R., Grimsby, J. Curr. Opin. Drug. Discov. Devel (2005)
- Metabolic diseases drug discovery world summit. July 28-29, 2003, San Diego, CA, USA. Sarabu, R. Expert. Opin. Investig. Drugs (2003)
- Oxazole- and imidazole-based Ser-Leu dipeptide mimetics in potent inhibitors of antigen presentation by MHC class II DR molecules. Sarabu, R., Bolin, D.R., Campbell, R., Cooper, J.R., Cox, D., Gaizband, D., Makofske, R., Nagy, Z., Olson, G.L. Drug. Des. Discov (2002)